Skip to main content

Esperion Therapeutics, Inc.

ESPRDelisted Jul 13, 2026
Industry
Pharmaceutical Preparations
SEC CIK
0001434868

Esperion Therapeutics, Inc. was delisted on Jul 13, 2026; its insiders filed their last Form 4 on Jul 13, 2026; 191 institutions reported holding it in 13F filings for Q2 2026, worth $646.8M in total; Soros Fund Management was the only superinvestor holding it.

13F holders, Q2 2025

Institutional positions in Esperion Therapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
164
−22 vs. Q1 2025
Shares held
98.2M
−15.4M (−13.5%) vs. Q1 2025
Total value
$96.6M
−$74.8M (−43.6%) vs. Q1 2025
New holders
14
57 more added
Sold out
36
39 more reduced

1 institution that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q1 2025: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting ESPR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ2 2025: 164 institutions
Q1 2021: 156 institutionsQ2 2021: 142 institutionsQ3 2021: 139 institutionsQ4 2021: 133 institutionsQ1 2022: 132 institutionsQ2 2022: 137 institutionsQ3 2022: 148 institutionsQ4 2022: 164 institutionsQ1 2023: 165 institutionsQ2 2023: 124 institutionsQ3 2023: 123 institutionsQ4 2023: 132 institutionsQ1 2024: 152 institutionsQ2 2024: 176 institutionsQ3 2024: 184 institutionsQ4 2024: 190 institutionsQ1 2025: 187 institutionsQ2 2025: 164 institutionsQ3 2025: 189 institutionsQ4 2025: 201 institutionsQ1 2026: 207 institutionsQ2 2026: 191 institutions
Value heldQ2 2025: $96.6M
Q1 2021: $805.3MQ2 2021: $599.4MQ3 2021: $299.4MQ4 2021: $268.0MQ1 2022: $241.2MQ2 2022: $352.1MQ3 2022: $425.5MQ4 2022: $457.6MQ1 2023: $129.1MQ2 2023: $103.6MQ3 2023: $75.9MQ4 2023: $215.3MQ1 2024: $336.2MQ2 2024: $304.2MQ3 2024: $214.3MQ4 2024: $277.9MQ1 2025: $171.5MQ2 2025: $96.6MQ3 2025: $286.1MQ4 2025: $559.6MQ1 2026: $479.3MQ2 2026: $646.8M
Institutions holding ESPR and their total value by quarter
QuarterHoldersValue
Q2 2026191$646.8M
Q1 2026207$479.3M
Q4 2025201$559.6M
Q3 2025189$286.1M
Q2 2025164$96.6M
Q1 2025187$171.5M
Q4 2024190$277.9M
Q3 2024184$214.3M
Q2 2024176$304.2M
Q1 2024152$336.2M
Q4 2023132$215.3M
Q3 2023123$75.9M
Q2 2023124$103.6M
Q1 2023165$129.1M
Q4 2022164$457.6M
Q3 2022148$425.5M
Q2 2022137$352.1M
Q1 2022132$241.2M
Q4 2021133$268.0M
Q3 2021139$299.4M
Q2 2021142$599.4M
Q1 2021156$805.3M

Institutions, Q2 2025

Shares, value and share of portfolio for each institution holding Esperion Therapeutics, Inc.; share changes are against Q1 2025.

Institutions holding ESPR in Q2 2025
InstitutionSharesValue% of portfolioChange in sharesAction
Delta Financial Group, Inc.––––Not filed